Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Autolus Therapeutics (AUTL) Operating Expenses (2017 - 2025)

Autolus Therapeutics (AUTL) has disclosed Operating Expenses for 6 consecutive years, with $92.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Operating Expenses rose 36.74% year-over-year to $92.8 million, compared with a TTM value of $325.1 million through Sep 2025, up 42.0%, and an annual FY2024 reading of $251.5 million, up 38.67% over the prior year.
  • Operating Expenses was $92.8 million for Q3 2025 at Autolus Therapeutics, up from $82.1 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $92.8 million in Q3 2025 and bottomed at $7.4 million in Q4 2022.
  • Average Operating Expenses over 4 years is $50.8 million, with a median of $48.8 million recorded in 2024.
  • Peak annual rise in Operating Expenses hit 618.71% in 2023, while the deepest fall reached 14.08% in 2023.
  • Year by year, Operating Expenses stood at $7.4 million in 2022, then soared by 618.71% to $53.3 million in 2023, then soared by 42.47% to $75.9 million in 2024, then grew by 22.3% to $92.8 million in 2025.
  • Business Quant data shows Operating Expenses for AUTL at $92.8 million in Q3 2025, $82.1 million in Q2 2025, and $74.2 million in Q1 2025.